Madrigal MASH drug beats expectations; Gilead cuts jobs; investment firm debuts

Gilead lays off 108 workers after Arcellx buyout; GSK-partnered LTZ Therapeutics has raised $38M; Madrigal’s MASH drug beats expectations; and more Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…

ENDPOINTS · 2026-05-06

🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, according to TD Cowen analysts. The Pennsylvania drugmaker ...

Source: Endpoints News